BERKELEY HEIGHTS, N.J.--(BUSINESS WIRE)--Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP) announced today that it will report results from a Phase I pharmacologic trial of sapacitabine (CYC682), a novel orally-available nucleoside analog, in patients with advanced leukemias or myelodysplastic syndromes (MDS), at the American Society of Clinical Oncology’s (ASCO) Annual Meeting at McCormick Place in Chicago. Details of the presentation are as follows:
